2024-515408-37-00RecruitingPhase 2
MRI with hyperpolarized pyruvate in gliblastoma - a phase II study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Nov 2025
Brief summary (registry, in English)
We hypothesis that tumor and therapy related changes in the brain tissue are associated with altered metabolic profiles and this is detectable with hyperpolarized [1-13C]pyruvate MRI.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 19 Jun 2024
- Start date
- 1 Apr 2020
- Lead sponsor
- Aarhus Universitet
- Diseases
- Glioblastoma
- EU CT number
- 2024-515408-37-00
- EudraCT number
- 2020-000310-15
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed high-grade glioma (grade 3 or 4) who are about to start radiotherapy.
- Age
- At least 18 years old.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed high-grade glioma (grade 3 and 4), scheduled for radiotherapy. WHO performance status 0-2.
- Earlier treatment
- No previous or current radiation or chemotherapy. No other investigational agents.
Main reasons for not taking part
- Allergy to pyruvate
- Cannot have an MRI (for example pacemaker, metal in the body, claustrophobia)
- Cannot have gadolinium contrast (eGFR 30 mL/min/1.73m2 or less, or earlier reactions to it)
- Expected remaining survival under 3 months
- Symptomatic heart disease, or history of alcohol abuse or illicit drug use
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not able or willing to receive radiotherapy
- Subjects who are receiving any other investigational agents.
- Previous or current treatment by radiation or chemotherapy.
Other illness
- History of alcohol abuse or illicit drug use.
- Allergy to pyruvate
- Contraindications to MRI o Pacemaker, neurostimulator or cochlea implant o Metal foreign bodies such as fragments and irremovable piercings o Unsafe medical implants (safety of heart valves, hips and the like must be confirmed) o Intracranial clips or coils o Claustrophobia o Largest circumference including arms > 160 cm
- Symptomatic cardiac disease (i.e. valve disease, coronary artery disease, arrythmias etc.). Hypertension and hyperlipidemia are allowed.
Lab values
- Contraindications to gadolinium contrast o eGFR ≤ 30 mL/min/1.73m2 o Previous adverse reactions to gadolinium
Other
- Predicted remaining survival <3 months
Who the study is looking for
- Patients with newly diagnosed high-grade glioma (grade 3 and 4)
- Scheduled for radiotherapy
- At least 18 years of age
- WHO performance status 0-2
- Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study. Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted.
- Danish speaking
- Able and willing to comply after informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus Universitet | Aarhus N | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.